- Home
- ZAPP vs APVO Comparison
ZAPP vs APVO Comparison
Compare ZAPP & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZAPP
- APVO
- Stock Information
- Founded
- ZAPP 2017
- APVO 2016
- Country
- ZAPP Thailand
- APVO United States
- Employees
- ZAPP N/A
- APVO N/A
- Industry
- ZAPP Motor Vehicles
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- ZAPP Consumer Discretionary
- APVO Health Care
- Exchange
- ZAPP Nasdaq
- APVO Nasdaq
- Market Cap
- ZAPP 4.6M
- APVO 5.4M
- IPO Year
- ZAPP N/A
- APVO N/A
- Fundamental
- Price
- ZAPP $0.80
- APVO $3.47
- Analyst Decision
- ZAPP
- APVO Strong Buy
- Analyst Count
- ZAPP 0
- APVO 1
- Target Price
- ZAPP N/A
- APVO $296.00
- AVG Volume (30 Days)
- ZAPP 1.7M
- APVO 44.0K
- Earning Date
- ZAPP 01-31-2025
- APVO 03-04-2025
- Dividend Yield
- ZAPP N/A
- APVO N/A
- EPS Growth
- ZAPP N/A
- APVO N/A
- EPS
- ZAPP N/A
- APVO N/A
- Revenue
- ZAPP $17,440.00
- APVO N/A
- Revenue This Year
- ZAPP $148,455.05
- APVO N/A
- Revenue Next Year
- ZAPP $544.47
- APVO N/A
- P/E Ratio
- ZAPP N/A
- APVO N/A
- Revenue Growth
- ZAPP N/A
- APVO N/A
- 52 Week Low
- ZAPP $0.70
- APVO $3.01
- 52 Week High
- ZAPP $19.10
- APVO $399.60
- Technical
- Relative Strength Index (RSI)
- ZAPP 37.29
- APVO 33.42
- Support Level
- ZAPP $0.74
- APVO $3.20
- Resistance Level
- ZAPP $0.95
- APVO $3.65
- Average True Range (ATR)
- ZAPP 0.10
- APVO 0.34
- MACD
- ZAPP 0.01
- APVO 0.01
- Stochastic Oscillator
- ZAPP 15.56
- APVO 31.51
About ZAPP Zapp Electric Vehicles Group Limited
Zapp Electric Vehicles Group Ltd designs manufactures, and sells high-performance electric vehicles, including maintenance and repair of electric vehicles and related parts and accessories.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.